Ignite Creation Date:
2024-05-06 @ 4:31 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05017766
Status:
RECRUITING
Last Update Posted:
2024-02-26
First Post:
2021-07-26
Brief Title:
NCCR AntiResist New Approaches to Combat Antibiotic-resistant Bacteria
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
NCCR AntiResist Mono-center Study to Identify New Approaches to Combat Antibiotic-resistant Bacteria
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AntiResist
Brief Summary:
This is an explorative mono-center study including prospectively collected patient samples from the University Hospital of Basel It is to investigate antimicrobial resistance AMR including three clinical manifestations of infectious diseases urinary tract infection pneumonia and deep-seated infections The focus is on four bacteria E coli Klebsiella species S aureus P aeruginosa that are part of the high priority list of World Health Organization WHO Residual patient samples are analysed for proteomic metabolomic and transcriptomic analysis immunocytochemical or fluorescence in-situ hybridisation FISH analysis flow cytometry analysis FACS and immunophenotyping and exploration of bacterial properties
Detailed Description:
The National Center of Competence in Research NCCR AntiResist aims at utilizing patient samples in order to investigate the physiology of bacterial pathogens in human patients and establishing a unique multidisciplinary network of clinicians biologists engineers chemists computational scientists and drug developers
The goal of this project is to elucidate the physiological properties of bacterial pathogens in infected human patients in order to provide new ways of combatting superbugs These clinical data will be used to guide and benchmark development of patient-mimicking and in-vitro models accelerate the search for novel bacterial targets antibacterial compounds and non-conventional strategies
In detail the focus will be on three clinical manifestations of infectious diseases caused by four critical bacterial pathogens belonging to WHO priority pathogens list E coli Klebsiella species S aureus and P aeruginosa
A Urinary tract infection B Pneumonia C Deep-seated infections D Controls for A B and C E Clinical controls for A B and C without obtained samples F Analysis whether the application of Art 34 HFV Weiterverwendung biologischen Materials undoder gesundheitsbezogener Personendaten für die Forschung bei fehlender Einwilligung und Information can avoid a bias
The goal of this project is to elucidate the physiological properties of bacterial pathogens in infected human patients in order to provide new ways of combatting superbugs These clinical data will be used to guide and benchmark development of patient-mimicking and in-vitro models accelerate the search for novel bacterial targets antibacterial compounds and non-conventional strategies
In detail the focus will be on three clinical manifestations of infectious diseases caused by four critical bacterial pathogens belonging to WHO priority pathogens list E coli Klebsiella species S aureus and P aeruginosa
A Urinary tract infection B Pneumonia C Deep-seated infections D Controls for A B and C E Clinical controls for A B and C without obtained samples F Analysis whether the application of Art 34 HFV Weiterverwendung biologischen Materials undoder gesundheitsbezogener Personendaten für die Forschung bei fehlender Einwilligung und Information can avoid a bias
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None